NCT02880475View on ClinicalTrials.gov

OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2014

Primary Completion Date

June 1, 2015

Study Completion Date

July 10, 2015

Conditions
Chronic Pain
Interventions
DRUG

OXN PR tablet

Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg

Trial Locations (1)

100032

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Mundipharma (China) Pharmaceutical Co. Ltd

INDUSTRY

NCT02880475 - OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients | Biotech Hunter | Biotech Hunter